Facial hair enhancement with minoxidil-an off-label use.

SAGE Open Med Case Rep

University of British Columbia, Vancouver, BC, Canada.

Published: February 2024

Minoxidil was first introduced in the 1970s as an anti-hypertensive medication. Hypertrichosis and scalp hair regrowth were noted by users, and the topical formulation of minoxidil was later approved by the Food and Drug Administration for androgenic alopecia and female pattern hair loss. Since then, minoxidil has been used off-label for various hair loss conditions and cosmetic outcomes. There are a multitude of informal reports on online communities presenting personal anecdotes regarding minoxidil's effectiveness as a facial hair enhancement tool; however, this has been seldom discussed in the literature. In this report, we will present a case of identical twin males, one of which used topical 5% minoxidil for over a year on the beard and mustache area, while the other abstained from using the medication.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894539PMC
http://dx.doi.org/10.1177/2050313X241231490DOI Listing

Publication Analysis

Top Keywords

facial hair
8
hair enhancement
8
hair loss
8
enhancement minoxidil-an
4
minoxidil-an off-label
4
minoxidil
4
off-label minoxidil
4
minoxidil introduced
4
introduced 1970s
4
1970s anti-hypertensive
4

Similar Publications

Hair Cortisol in Young Children with Autism and Their Parents: Associations with Child Mental Health, Eating Behavior and Weight Status.

J Autism Dev Disord

January 2025

Sarr Autism Rotterdam, Youz Child- and Adolescent Psychiatry, Parnassia Group, Dynamostraat 18, Rotterdam, The Netherlands.

Children with autism and their parents face daily challenges that may be stressful for both. However, little is known about biological stress (hair cortisol concentrations [HCC]) in these families and its connection to children's health outcomes. This study investigates biological stress in children with autism and their parents and its associations with child mental health, eating behavior and BMI.

View Article and Find Full Text PDF

Dermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report.

Clin Cosmet Investig Dermatol

January 2025

Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr Hasan Sadikin Hospital, Bandung, West Java, Indonesia.

Epidermal growth factor receptor inhibitors (EGFRI) are biological factors used in several types of cancer, including non-small-cell lung cancers (NSCLC). One of the EGFR inhibitors that has been approved for NSCLC is afatinib. Dermatologic adverse events are the most commonly reported and may impair the patient's compliance to the therapy as it causes aesthetic discomfort and significantly impact the patient's quality of life.

View Article and Find Full Text PDF

Exosomes in Facial Plastic Surgery.

Facial Plast Surg

January 2025

Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.

Exosomes have emerged as a promising therapeutic frontier in facial plastic surgery. Preclinical studies have demonstrated their ability to modulate wound healing, skin rejuvenation, hair growth, and nerve regeneration. Early clinical evidence suggests potential benefits in enhancing recovery after laser resurfacing, treating acne scars, and promoting hair growth.

View Article and Find Full Text PDF

Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RNAseq Analysis.

Clin Cosmet Investig Dermatol

January 2025

Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, 510091, People's Republic of China.

Background: Alopecia areata (AA) is a common autoimmune disease, causes sudden hair loss on the scalp, face, and sometimes other areas of the body. Previous studies have suggested more severe manifestations and higher recurrence rates in children than in adults. Moreover, pediatric AA patients with atopic predisposition often exhibit elevated IgE levels, early onset, and a poor prognosis.

View Article and Find Full Text PDF

Cross-trait multivariate GWAS confirms health implications of pubertal timing.

Nat Commun

January 2025

Laboratory of Molecular Translational Medicine, Center for Translational Medicine, West China Second University Hospital, Sichuan University, Chengdu, China.

Pubertal timing is highly variable and is associated with long-term health outcomes. Phenotypes associated with pubertal timing include age at menarche, age at voice break, age at first facial hair and growth spurt, and pubertal timing seems to have a shared genetic architecture between the sexes. However, puberty phenotypes have primarily been assessed separately, failing to account for shared genetics, which limits the reliability of the purported health implications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!